Pain & Central Nervous System Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain & Central Nervous System Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Pacira's Phase III Study of EXPAREL(TM) Meets Primary Pain Relief Endpoint
November 2nd, 2009
Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, announced that its Phase III study of its new analgesic EXPAREL™ (DepoBupivacaine) in patients undergoing a bunionectomy procedure met its primary endpoint. The multicenter, randomized, double-blind, parallel-group, placebo controlled study showed a statistically significant reduction in area under the curve analysis (AUC) of the NRS scores in the subjects receiving EXPAREL™ compared to placebo (p=3D0.0005) over the first 24 hours following surgery; the difference continued to be statistically significant through 36 hours. Pain scores in both groups declined after 36 hours. The...
Source: Pain & Central Nervous System Week (2009-11-02)
|
